Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis.
about
A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.FLT3: ITDoes matter in leukemia.Considerations for targeting malignant stem cells in leukemia.Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas.Screening patients with polycythemia vera for c-Kit mutations.
P2860
Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mutational analysis of class I ...... ) in idiopathic myelofibrosis.
@ast
Mutational analysis of class I ...... ) in idiopathic myelofibrosis.
@en
Mutational analysis of class I ...... ) in idiopathic myelofibrosis.
@nl
type
label
Mutational analysis of class I ...... ) in idiopathic myelofibrosis.
@ast
Mutational analysis of class I ...... ) in idiopathic myelofibrosis.
@en
Mutational analysis of class I ...... ) in idiopathic myelofibrosis.
@nl
prefLabel
Mutational analysis of class I ...... ) in idiopathic myelofibrosis.
@ast
Mutational analysis of class I ...... ) in idiopathic myelofibrosis.
@en
Mutational analysis of class I ...... ) in idiopathic myelofibrosis.
@nl
P2093
P2860
P1476
Mutational analysis of class I ...... ) in idiopathic myelofibrosis.
@en
P2093
Faisel M Abu-Duhier
Gill A Wilson
Ian R Peake
John T Reilly
Mamdooh Gari
Rory S Care
P2860
P304
P356
10.1046/J.1365-2141.2003.04108.X
P407
P577
2003-02-01T00:00:00Z